<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ACETAZOLAMIDEÂ - acetazolamide sodiumÂ injection, powder, lyophilized, for solutionÂ </strong><br>Heritage Pharmaceuticals Inc.<br></p></div>
<h1>For Intravenous use<br>Rx Only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<br><p class="First">Acetazolamide, an inhibitor of the enzyme carbonic anhydrase, is a white to faintly yellowish white crystalline, odorless powder, weakly acidic,Â very slightly soluble in water and slightly soluble in alcohol. The chemical name for acetazolamide is <span class="Italics">N</span>-(5-Sulfamoyl-1, 3, 4-thiadiazol-2yl)-acetamide and has the following structural formula:</p>
<br><div class="Figure"><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=60f656ff-97b1-4a89-99af-8100483c2bac&amp;name=acetazolamide-1c.jpg"></div>
<br><p>MW 222.25Â Â Â Â Â Â Â Â Â Â Â Â Â  C<span class="Sub">4</span>H<span class="Sub">6</span>N<span class="Sub">4</span>O<span class="Sub">3</span>S<span class="Sub">2</span><br>Acetazolamide is available for intravenous use, and is supplied as a sterile powder requiring reconstitution. Each vial contains acetazolamide sodium equivalent to 500 mg of acetazolamide. The bulk solution is adjusted to pH 9.6 using sodium hydroxide NF and, if necessary, hydrochloric acid NF prior to lyophilization. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<br><p class="First">Acetazolamide is a potent carbonic anhydrase inhibitor, effective in the control of fluid secretion (e.g., some types of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>), in the treatment of certain <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span> (e.g., <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>) and in the promotion of <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> in instances of abnormal <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> (e.g., cardiac <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>).<br>Acetazolamide is not a mercurial diuretic. Rather, it is a nonbacteriostatic sulfonamide possessing a chemical structure and pharmacological activity distinctly different from the bacteriostatic sulfonamides.<br>Acetazolamide is an enzyme inhibitor that acts specifically on carbonic anhydrase, the enzyme that catalyzes the reversible reaction involving the hydration of <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> and the <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> of carbonic acid. In the eye, this inhibitory action of acetazolamide decreases the secretion of aqueous humor and results in a drop in intraocular pressure, a reaction considered desirable in cases of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> and even in certain nonglaucomatous conditions. Evidence seems to indicate that acetazolamide has utility as an adjuvant in the treatment of certain dysfunctions of the central nervous system (e.g., <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>). Inhibition of carbonic anhydrase in this area appears to retard abnormal, paroxysmal, excessive discharge from central nervous system neurons. The <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuretic effect</span> of acetazolamide is due to its action in the kidney on the reversible reaction involving hydration of <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> of carbonic acid.<br>The result is renal loss of HCO<span class="Sub">3</span> ion, which carries out sodium, water, and potassium. Alkalinization of the urine and promotion of <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> are thus effected. Alteration in <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> metabolism occurs due to increased reabsorption of <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> by the renal tubules as a result of urinary alkalinization.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First">For adjunctive treatment of: <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> due to <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>; drug-induced <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>; centrencephalic epilepsies (<span class="product-label-link" type="condition" conceptid="4194232" conceptname="Absence seizure">petit mal</span>, unlocalized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>); chronic simple (open-angle) <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, secondary <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, and preoperatively in acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> where delay of surgery is desired in order to lower intraocular pressure.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<br><p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to acetazolamide or any excipients in the formulation. Since acetazolamide is a sulfonamide derivative, cross sensitivity between acetazolamide, sulfonamides and other sulfonamide derivatives is possible.<br>Acetazolamide therapy is contraindicated in situations in which sodium and/or potassium blood serum levels are depressed, in cases of marked kidney and liver disease or dysfunction, in suprarenal gland failure, and in <span class="product-label-link" type="condition" conceptid="4108257" conceptname="Metabolic acidosis, NAG, acidifying salts">hyperchloremic acidosis</span>. It is contraindicated in patients with cirrhosis because of the risk of development of <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>.<br>Long-term administration of acetazolamide is contraindicated in patients with chronic noncongestive angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> since it may permit organic closure of the angle to occur while the worsening <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> is masked by lowered intraocular pressure.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<br><p class="First">Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, and other <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>. Sensitizations may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> or other serious reactions occur, discontinue use of this drug.<br>Caution is advised for patients receiving concomitant high-dose aspirin and acetazolamide, as <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>GENERAL</h2>
<br><p class="First">Increasing the dose does not increase the <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> and may increase the incidence of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and/or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>. Increasing the dose often results in a decrease in <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>. Under certain circumstances, however, very large doses have been given in conjunction with other diuretics in order to secure <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> in complete refractory failure.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<br><p class="First">Adverse reactions common to all sulfonamide derivatives may occur: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (including <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>), <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal calculus</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>. Precaution is advised for early detection of such reactions and the drug should be discontinued and appropriate therapy instituted.<br>In patients with pulmonary obstruction or <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span> where alveolar ventilation may be impaired, acetazolamide which may precipitate or aggravate <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> should be used with caution.<br>Caution is advised for patients receiving concomitant high-dose aspirin and acetazolamide, as <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported (see <a href="#Section_5">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="Section_6.3"></a><a name="section-6.3"></a><p></p>
<h2>Laboratory Tests</h2>
<br><p class="First">To monitor for hematologic reactions common to all sulfonamides, it is recommended that a baseline CBC and platelet count be obtained on patients prior to initiating acetazolamide therapy and at regular intervals during therapy. If significant changes occur, early discontinuance and institution of appropriate therapy are important. Periodic monitoring of serum electrolytes is recommended.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_6.6"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis &amp; Mutagenesis &amp; Impairment Of Fertility</h2>
<br><p class="First">Long-term studies in animals to evaluate the carcinogenic potential of acetazolamide have not been conducted. In a bacterial mutagenicity assay, acetazolamide was not mutagenic when evaluated with and without metabolic activation.<br>The drug had no effect on fertility when administered in the diet to male and female rats at a daily intake of up to 4 times the recommended human dose of 1000 mg in a 50 kg individual.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_6.7"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<br><p class="First"><span class="Bold">Teratogenic Effects</span><br><br><span class="Bold">Pregnancy Category C</span>: Acetazolamide, administered orally or parenterally, has been shown to be teratogenic (defects of the limbs) in mice, rats, hamsters and rabbits. There are no adequate and well-controlled studies in pregnant women. Acetazolamide should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_6.9"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Because of the potential for serious adverse reaction in nursing infants from acetazolamide, a decision should be made whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_6.10"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use</h2>
<br><p class="First">The safety and effectiveness of acetazolamide in children have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<br><p class="First">Adverse reactions, occurring most often early in therapy, include <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, particularly a â€œtinglingâ€? feeling in the extremities, hearing dysfunction or <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, loss of appetite, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste alteration</span> and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>; <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, and occasional instances of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.<br><span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic acidosis</span> and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> may occur.<br>Transient <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span> has been reported. This condition invariably subsides upon diminution or discontinuance of the medication. Other occasional adverse reactions include <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, <span class="product-label-link" type="condition" conceptid="4193951" conceptname="Flaccid paralysis">flaccid paralysis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. Also see <a href="#Section_6">PRECAUTIONS</a> : Information for Patients for possible reactions common to sulfonamide derivatives. Fatalities have occurred although rarely, due to severe reactions to sulfonamides including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> and other <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span> (see <a href="#Section_5">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_9"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<br><p class="First">No data are available regarding acetazolamide overdosage in humans as no cases of acute <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> with this drug have been reported.<br>Animal data suggest that acetazolamide is remarkable nontoxic. No specific antidote is known. Treatment should be symptomatic and supportive.<br><span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte imbalance</span>, development of an acidotic state, and central nervous effects might be expected to occur. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored.<br>Supportive measures are required to restore electrolyte and pH balance. The acidotic state can usually be corrected by the administration of <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>.<br>Despite its high intraerythrocytic distribution and plasma protein binding properties, acetazolamide may be dialyzable. This may be particularly important in the management of acetazolamide overdosage when complicated by the presence of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<br><p class="First"><span class="Bold">Preparation and Storage of Parenteral Solution</span><br><br>Each 500 mg vial containing sterile acetazolamide sodium should be reconstituted with at least 5 mL of Sterile Water for Injection prior to use. Reconstituted solutions retain their physical and chemical properties for 3 days under refrigeration at 2Â° to 8Â°C (36Â° to 46Â°F), or 12 hours at room temperature 20Â° to 25Â°C (68Â° to 77Â°F). <span class="Bold">CONTAINS NO PRESERVATIVE</span>. The direct intravenous route of administration is preferred. Intramuscular administration is not recommended.<br><span class="Bold"><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span>: </span>Acetazolamide should be used as an adjunct to the usual therapy. The dosage employed in the treatment of chronic simple (open-angle) <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> ranges from 250 mg to 1 g of acetazolamide per 24 hours, usually in divided doses for amounts over 250 mg. It has usually been found that a dosage in excess of 1 g per 24 hours does not produce an increased effect. In all cases, the dosage should be adjusted with careful individual attention both to symptomatology and ocular <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>. Continuous supervision by a physician is advisable.<br>In treatment of secondary <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> and in the preoperative treatment of some cases of acute congestive (closed-angle) <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, the preferred dosage is 250 mg every four hours, although some cases have responded to 250 mg twice daily on short-term therapy.<br>In some acute cases, it may be more satisfactory to administer an initial dose of 500 mg followed by 125 or 250 mg every four hours depending on the individual case. Intravenous therapy may be used for rapid relief of ocular <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> in acute cases. A complementary effect has been noted when acetazolamide has been used in conjunction with miotics or mydriatics as the case demanded.<br><span class="Bold"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span>: </span>It is not clearly known whether the beneficial effects observed in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> are due to direct inhibition of carbonic anhydrase in the central nervous system or whether they are due to the slight degree of <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> produced by the divided dosage. The best results to date have been seen in <span class="product-label-link" type="condition" conceptid="4194232" conceptname="Absence seizure">petit mal</span> in children. Good results, however, have been seen in patients, both in children and adult, in other types of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> such as <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal</span>, mixed <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> patterns, myoclonic jerk patterns, etc. The suggested total daily dose is 8 to 30 mg per kg in divided doses. Although some patients respond to a low dose, the optimum range appears to be from 375 to 1000 mg daily. However, some investigators feel that daily doses in excess of 1 g do not produce any better results than a 1 g dose. When acetazolamide is given in combination with other anticonvulsants, it is suggested that the starting dose should be 250 mg once daily in addition to the existing medications. This can be increased to levels as indicated above.<br>The change from other medications to acetazolamide should be gradual and in accordance with usual practice in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> therapy.<br><span class="Bold"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span>: </span>For <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> in <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, the starting dose is usually 250 to 375 mg once daily in the morning (5 mg/kg). If, after an initial response, the patient fails to continue to lose <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> fluid, do not increase the dose but allow for kidney recovery by skipping medication for a day.<br>Acetazolamide yields best diuretic results when given on alternate days, or for two days alternating with a day of rest.<br>Failures in therapy may be due to overdosage or too frequent dosage. The use of acetazolamide does not eliminate the need for other therapy such as digitalis, bed rest, and salt restriction.<br><span class="Bold">Drug-Induced <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>: </span>Recommended dosage is 250 to 375 mg of acetazolamide once a day for one or two days, alternating with a day of rest.<br><span class="Bold">Note: </span>The dosage recommendations for <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> and <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> differ considerably from those for <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, since the first two conditions are not dependent upon carbonic anhydrase inhibition in the kidney which requires intermittent dosage if it is to recover from inhibitory effect of the therapeutic agent.<br>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<br><p class="First">Acetazolamide for Injection USP is a white powder.<br><span class="Bold">Intravenous Acetazolamide for Injection USP (lyophilized) powder.</span><br>Supplied as single vial of 500 mg in a carton (NDC 23155-313-31)<br><span class="Bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F) excursions permitted between 15Â° to 30Â°C (59Â° to 86Â°F) [see USP Controlled Room Temperature]. </span><span class="Bold">Reconstituted solution should be stored in refrigerator at 2Â° to 8Â°C (36Â° to 46Â°F). Use within 12 hours of reconstitution. Contains no preservative. Discard unused portion.</span></p>
<br><br><p>Manufactured by:</p>
<p><span class="Bold">Emcure Pharmaceuticals Ltd., <br></span>Hinjwadi, Pune, India.</p>
<br><p>Manufactured for:</p>
<p><span class="Bold">Heritage Pharmaceuticals Inc.</span></p>
<p>Eatontown, NJ 07724</p>
<p>1.866.901.DRUG (3784)</p>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_18"></a><a name="section-11"></a><p></p>
<h1>Principal display panel- label</h1>
<br><p class="First">AcetaZOLAMIDEÂ for injection USP<br>500 mg<br>For IV Use<br>NDCÂ 23155-313-31<br><span class="Bold">Rx only</span><br><span class="Bold">Each vial contains:</span> Acetazolamide Sodium equivalent to 500 mg Acetazolamide USP and pH adjusted to approximately 9.6 with Sodium Hydroxide NF and, if necessary, Hydrochloric Acid NF.<br><span class="Bold">Store at 20</span><span class="Bold">Â° to 25Â°C (68Â° to 77Â°F) excursions permitted between 15Â° to 30Â°C (59Â° to 86Â°F) [see USP Controlled Room Temperature].</span><br>Store reconstituted solution in refrigerator at 2Â° to 8Â°C (36Â° to 46Â°F).<br>Use within 12 hours of reconstitution.<br><span class="Bold">Must be reconstituted. </span>See insert.<br><span class="Bold">Discard unused portion.<br></span>Manufactured by:<br><span class="Bold">Emcure Pharmaceuticals Ltd.,<br></span>Hinjwadi, Pune,Â India.<br>Manufactured for:<br><span class="Bold">Heritage Pharmaceuticals Inc.</span><br>Eatontown, NJ 07724</p>
<br><div class="Figure"><img alt="label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=60f656ff-97b1-4a89-99af-8100483c2bac&amp;name=acetazolamide-2c.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_19"></a><a name="section-12"></a><p></p>
<h1>Principal display panel- carton</h1>
<br><p class="First">AcetaZOLAMIDEÂ for injectionÂ USP<br>500 mg<br>For IV Use<br>NDCÂ 23155-313-31<br><span class="Bold">Rx only</span><br><span class="Bold">Each vial contains: </span>Acetazolamide Sodium equivalent to 500 mg Acetazolamide USP and pH adjusted to approximately 9.6 with Sodium Hydroxide NF and, if necessary, Hydrochloric Acid NF.<br><span class="Bold">Must be reconstituted. </span>See insert.<br>Store reconstituted solution in refrigerator at 2Â° to 8Â°C (36Â° to 46Â°F).<br><span class="Bold">USUAL DOSAGE: </span>See package insert.<br>Use within 12 hours of reconstitution. Contains no preservative.<br><span class="Bold">Store at 20</span><span class="Bold">Â° to 25Â°C (68Â° to 77Â°F) excursions permitted between 15Â° to 30Â°C (59Â° to 86Â°F) [see USP Controlled Room Temperature].</span><br><span class="Bold">Discard unused portion.<br></span>Manufactured by:<br><span class="Bold">Emcure Pharmaceuticals Ltd.,<br></span>Hinjwadi, Pune, India.<br>Manufactured for:<br><span class="Bold">Heritage Pharmaceuticals Inc.<br></span>Eatontown, NJ 07724<br>1.866.901.DRUG (3784)</p>
<br><div class="Figure"><img alt="carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=60f656ff-97b1-4a89-99af-8100483c2bac&amp;name=acetazolamide-3c.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACETAZOLAMIDEÂ 		
					</strong><br><span class="contentTableReg">acetazolamide injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:23155-313</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ACETAZOLAMIDE SODIUM</strong> (ACETAZOLAMIDE) </td>
<td class="formItem">ACETAZOLAMIDE</td>
<td class="formItem">500Â mg Â inÂ 5Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:23155-313-31</td>
<td class="formItem">5 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202693</td>
<td class="formItem">12/19/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Heritage Pharmaceuticals Inc.
							(780779901)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Emcure Pharmaceuticals Ltd. (916921919)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Emcure Pharmaceuticals Limited</td>
<td class="formItem"></td>
<td class="formItem">862602830</td>
<td class="formItem">ANALYSIS(23155-313), LABEL(23155-313), MANUFACTURE(23155-313), PACK(23155-313)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>396437d2-b2ca-4220-ba21-cb3616708cd4</div>
<div>Set id: 60f656ff-97b1-4a89-99af-8100483c2bac</div>
<div>Version: 3</div>
<div>Effective Time: 20141225</div>
</div>
</div>Â <div class="DistributorName">Heritage Pharmaceuticals Inc.</div></p>
</body></html>
